These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11812424)

  • 41. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin.
    Schmidt-Erfurth UM; Michels S
    Ophthalmology; 2003 Jul; 110(7):1306-14. PubMed ID: 12867383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute respiratory distress due to verteporfin infusion for photodynamic therapy.
    Fossarello M; Peiretti E
    Arch Ophthalmol; 2006 Oct; 124(10):1509-10. PubMed ID: 17030732
    [No Abstract]   [Full Text] [Related]  

  • 43. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
    Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
    Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Pieramici DJ; Bressler SB; Koester JM; Bressler NM
    Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
    Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
    Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial.
    Kaiser PK;
    Curr Med Res Opin; 2009 Aug; 25(8):1853-60. PubMed ID: 19530976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization.
    Gelisken F; Inhoffen W; Partsch M; Schneider U; Kreissig I
    Am J Ophthalmol; 2001 Apr; 131(4):518-20. PubMed ID: 11292425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.
    Sharp DM; Lai S; Markey CM
    Clin Exp Ophthalmol; 2007; 35(1):24-31. PubMed ID: 17300567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin.
    Jampol LM; Scott L
    Am J Ophthalmol; 2002 Jul; 134(1):99-101. PubMed ID: 12095815
    [No Abstract]   [Full Text] [Related]  

  • 53. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study.
    Rosenfeld PJ; Boyer DS; Bressler NM; Fish G; Grizzard WS; Hao Y; Hnik P; Hudson HL; Singerman L; Slakter JS;
    Am J Ophthalmol; 2007 Dec; 144(6):970-972. PubMed ID: 18036873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks.
    Karacorlu M; Karacorlu S; Ozdemir H; Mat C
    Am J Ophthalmol; 2002 Sep; 134(3):360-6. PubMed ID: 12208247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization.
    Park CH; Toth CA
    Am J Ophthalmol; 2003 Nov; 136(5):830-5. PubMed ID: 14597033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
    Chaudhary V; Mao A; Hooper PL; Sheidow TG
    Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
    Ergun E; Maár N; Ansari-Shahrezaei S; Wimpissinger B; Krepler K; Wedrich A; Stur M
    Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M; Gelisken F; Ziemssen F; Wachtlin J; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
    N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.